Breaking News, Financial News

Biogen 4Q Results

Revenue from product launches offset decline in multiple sclerosis product revenue, down 8% to $1.1 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen 4Q Revenues: $2.5 billion (+3%) 4Q Earnings: $267 million (+7%) FY Revenues: $9.7 billion (-2%) FY Earnings: $1.6 billion (+41%) Comments: Revenue from product launches offset decline in multiple sclerosis product revenue, down 8% to $1.1 billion. Tecfidera sales were $227.8 million, down 7% and Vumerity sales were $176.6 million, up 13%. Avonex sales were $170 million, down 17%. Tysabri sales were $415.4 million, down 11%. Rare Disease revenue was $535.3 million in the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters